Document Mentions (4 shared documents)

EFTA00135754

2 mentions1 same-page

Page ?Same page

valescent plasma in comparison to remdesivir for the treatment of coronavirus. The NIAID- funded study, led by a group of companies including Japan's Takeda Pharmaceutical, will include 500 patients across six continents. WSJournal Analysis: Vaccine Trial Participants Focus On Ending Pandemic. The Wall Street Journal

nd Up To Trump. • AP Analysis: Healthcare Professionals "Battle Virus Skeptics." • Moderna To Forgo Patents Related To COVID Vaccine. • Regeneron, Eli Lilly Ask For FDA EUAs. • NIAID Marks Start Of Convalescent Plasma Study. • WSJournal Analysis: Vaccine Trial Participants Focus On Ending Pandemic. • New Y

EFTA00136798

2 mentions1 same-page

Page ?Same page

alescent plasma in comparison to remdesivir for the treatment of coronavirus. The NIAID-funded study, led by a group of companies including Japan's Takeda Pharmaceutical, will include 500 patients across six continents. WSJoumal Analysis: Vaccine Trial Participants Focus On Ending Pandemic. The Wall Street Journal <

and Up To Trump. • AP Analysis: Healthcare Professionals "Battle Virus Skeptics." • Modema To Forgo Patents Related To COVID Vaccine. • Regeneron, Eli Lilly Ask For FDA EUAs. • NIAID Marks Start Of Convalescent Plasma Study. • WSJournal Analysis: Vaccine Trial Participants Focus On Ending Pandemic. • New Y

EFTA00148778

2 mentions1 same-page

Page ?Same page

valescent plasma in comparison to remdesivir for the treatment of coronavirus. The NIAID- funded study, led by a group of companies including Japan's Takeda Pharmaceutical, will include 500 patients across six continents. WS.Journal Analysis: Vaccine Trial Participants Focus On Ending Pandemic. The Wall Street Journa